Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00— vs Q3 2020 Net Income-$71.05K-$71.05KN/M vs Q3 2020 EPS Diluted$0.00$0.00— vs Q3 2020 Operating Income-$66,248N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end